Market Access
NICE rejects BMS' Zeposia MS pill in provisional guidance
NICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing multiple sclerosis in first draft guidance.
